Quest Diagnostics Inc. | Separate Chair & CEO at Quest Diagnostics Inc.

Status
Filed
Previous AGM date
Resolution details
Company ticker
DGX
Lead filer
John Chevedden
Resolution ask
Adopt or amend a policy
ESG theme
  • Governance
ESG sub-theme
  • CEO / chair duality
Type of vote
Shareholder proposal
Filer type
Shareholder
Company sector
Health Care
Company HQ country
United States
Resolved clause
RESOLVED : Shareholders request that the Board of Directors adopt an enduring policy, and amend the governing documents as necessary including the Corporate Governance Guidelines in order that 2 separate people hold the office of the Chairman and the office of the CEO as soon as possible.
Supporting statement
The Chairman of the Board shall be an Independent Director. An independent Lead Director shall not be a substitute for an independent Board Chairman. The Board shall have the discretion to select an interim Chairman of the Board, who is not an Independent Director, to serve while the Board is required to seek an Independent Chairman of the Board on an accelerated basis. This policy could be phased in when there is a contract renewal for our current CEO or for the next CEO transition although it is better to adopt it now to obtain the maximum benefit. An independent Board Chairman at all times improves corporate governance by bringing impartiality, objective oversight, and external expertise to board decisions, mitigating conflicts of interest, enhancing transparency, and boosting shareholder confidence. This detached perspective allows the chairman to focus on shareholder interests , strengthen management accountability, and provide critical checks and balances, ultimately contributing to long-term sustainability and credibility. Now could be a ripe time for this policy since Quest Diagnostics stock was at $174 in 2021 and at only $176 in late 2025 despite a robust stock market. Plus challenging news reports regarding Quest Diagnostics emerged in 2025. Lawsuits related to a major 2019 data breach continued into 2025. The data breach exposed the personal, medical, and financial information of 12 million patients through a third-party vendor, American Medical Collection Agency (AMCA). These lawsuits charge that Quest failed to properly safeguard patient information and ensure its vendors had adequate security measures in place. Quest Diagnostics is regularly mentioned in legal information resources (like law firm websites) as a defendant in malpractice lawsuits related to alleged lab errors and diagnostic failures, some with severe outcomes. A February 2024 settlement with the California Attorney General's office, which resulted in Quest paying a penalty for unlawfully disposing of hazardous waste, medical waste, and protected health information at its facilities, was discussed in subsequent 2025 legal summaries. A Guardian investigation said that Quest Diagnostics' drug tests used in California prisons yielded thousands of potential false positives for an extended period. A data analysis suggested more than 5,000 potential false positives, with one expert stating the high positivity rates rendered the tests "basically worthless." During its Q2 2025 earnings call, Quest Diagnostics highlighted potential future challenges, including the impact of government healthcare legislation (referred to as the "One Big Beautiful Bill," which could result in more uninsured patients) and the effects of tariffs from China and Europe on the bottom line.

DISCLAIMER: By including a shareholder resolution or management proposal in this database, neither the PRI nor the sponsor of the resolution or proposal is seeking authority to act as proxy for any shareholder; shareholders should vote their proxies in accordance with their own policies and requirements.

Any voting recommendations set forth in the descriptions of the resolutions and management proposals included in this database are made by the sponsors of those resolutions and proposals, and do not represent the views of the PRI.

Information on the shareholder resolutions, management proposals and votes in this database have been obtained from sources that are believed to be reliable, but the PRI does not represent that it is accurate, complete, or up-to-date, including information relating to resolutions and management proposals, other signatories’ vote pre-declarations (including voting rationales), or the current status of a resolution or proposal. You should consult companies’ proxy statements for complete information on all matters to be voted on at a meeting.